Table 2 Treatment-related toxicities occurring in ≥10% of patients (N, %)

From: Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

Dose

195 mg/m2

390 mg/m2

450 mg/m2

550 mg/m2

Total

N

10

17

11

4

42

 

Grade 1–2

Grade 3–4

Grade 1–2

Grade 3–4

Grade 1–2

Grade 3–4

Grade 1–2

Grade 3–4

Grade 1–2

Grade 3–4

Anaemia

8 (80)

2 (20)

14 (82)

3 (18)

11 (100)

4 (36)

3 (75)

1 (25)

36 (86)

10 (24)

Fatigue

2 (20)

0 (0)

7 (41)

1 (6)

6 (55)

0 (0)

2 (50)

1 (25)

17 (40)

2 (2)

Hypoxia

0 (0)

2 (20)

1 (6)

5 (29)

2 (18)

1 (9)

0 (0)

3 (75)

3 (7)

11 (26)

Vomiting

1 (10)

1 (10)

2 (12)

1 (6)

0 (0)

0 (0)

2 (50)

0 (0)

5 (12)

2 (5)

Nausea

1 (10)

1 (10)

1 (6)

0 (0)

1 (9)

0 (0)

3 (75)

0 (0)

6 (14)

1 (2)